⚠️ Uptrend Under Pressure Severe risk · 99 · Institutional selling is building — 6 distribution days in the last 25 sessions. · 6 distribution days (SPY) Full briefing → Jul 28
Simple research view

CVS · CVS Health Corporation

$107.07 latest stored close
Detected setup Wyckoff SOS

Watch · Quality 22/100

Ask about CVS

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

Scans / Retail Trade / CVS

$CVS

CVS Health Corporation

CVS Health Corporation is a large-cap Drugstore Chains company in the Retail Trade sector with a market cap of $137B.

Strong Buy · 87 Retail Trade Drugstore Chains stock Stage 2 · Advancing Base 2 Data 5m ago
$107.07 latest close
Council read · 6 methods

Watch — evidence is building

0 buyable · 6 watch · 0 avoid. Review the observed passes and blockers before reading the chart.

Earnings-risk mode

Pre-earnings setup

Thursday, July 30, 2026 Time not confirmed No sourced report session or clock time

Deterministic evidence

CVS-0.62%
Broad market · SPY+0.02%
Same completed session window ending 2026-07-27. -0.64 points vs SPY.
CatalystUnavailable Stock reactionNegative Sector reactionUnavailable Opening surgeUnavailable Event riskEarnings-driven
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

AI interpretation (optional)

Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.

Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.
Price $107.07 Jul 27 close
52W High $110.68 -3.3%
52W Low $58.99
Wks Since High 0w
Base Depth -4.8%
Base B2
SMA 50 $100.27
SMA 200 $84.00
Avg Vol 8,025,784
RS Rank 90
RS vs High -2.0%
RS Slope +3.6% ▲
Grp Rank #4/64
ADR% 2.3%
ATR(14) $2.55 (2.4%)
Rel Vol (today) 0.98×
Vol Pace N/A
U/D Vol 1.05
A/D Days 20A / 9D
A/D Rating A+
VDU Bars 0/10 d
Power Trend 30d
Earnings 2d
$58.99
$110.68 93%

CVS Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for CVS.

Create Free Account
Setup Quality B+ 5/7 signals
Jul 24: 94 (Trend Only)Jul 24: 94 (Trend Only)Jul 27: 94 (Trend Only)Jul 28: 55 (Wyckoff SOS)55 Score trend
✓ Stage 2 · Advancing ✓ Power Trend 30d ✗ RS New High ✓ Trend 8/8 ✗ No Pattern ✓ CANSLIM 76.6 (B) ✓ Gatekeeper Base #2 (B)

See the full conviction stack.

Unlock Insights

Technical Analysis Report Card

$CVS · $107.07 · as of 2026-07-27 · multi-factor read
87
/ 100
Strong Buy

Trend · Daily / Weekly / Monthly

Daily ▲ Uptrend
Weekly ▲ Uptrend
Monthly ▲ Uptrend

Moving Averages

50-day$100.27 ↑
100-day$89.28 ↑
200-day$84.00 ↑
Bullish (50 > 200)

RSI (14)

Reading58.9 · Bullish

Bullish momentum — comfortably in buyer territory.

MACD (12/26/9)

StateWeakening
Histogram-0.257

Weakening — MACD slipped below its signal line. Histogram contracting.

Bollinger Bands (20,2)

%B / Width66% · 7.9%
Squeeze — volatility compressing

Mid-band — no directional band edge in play. Bands are squeezing — volatility is compressing, often a precursor to a sharp move.

Volume · Buyer vs Seller

Up/Down vol1.05 · Neutral
Rel volume0.98×

Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.

Support & Resistance

R · $110.6852-week high
Price · $107.07now
S · $101.78swing level
S · $89.42swing level
S · $78.22swing level

Fibonacci · Uptrend swing

23.6%$100.96
38.2%$94.95
50.0%$90.09
61.8%$85.24
78.6%$78.32

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for CVS — plus the full 495-symbol scanner and Ask-the-Legends chat.
🔒 Start your 7-day free trial →
Daily uptrendWeekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishRS 87 (leader)
Want this read in a legend's voice? 💬 Ask a Legend about CVS
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 🟡 6 of 6 legends are Watching — building, not yet a confirmed buy.
Watch
Minervini B

Trend-template read: 9/12 pass; wait for the soft misses to improve.

Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $107.07, MA150 $85.67, MA200 $84.00
1.2 150-day MA > 200-day MAMA150 $85.67 vs MA200 $84.00
Failing evidence
2. ROE ≥ 17%ROE 3.9%
2. Revenue growth ≥ 20% YoY+7.8% YoY
9/12 checks
Watch
O'Neil D

CANSLIM read: 4/8 pass; improvement is still needed.

Passing evidence
C: Quarterly EPS acceleration ≥ 25%+135.8% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 87
Failing evidence
A: Annual earnings & revenue qualityRev +7.8% | ROE 3.9%
S: Volume ≥ 40% above average on breakoutVolume ratio 0.98x
4/8 checks
Watch
Weinstein B

Stage-analysis read: Stage 2 is present; 1 supporting checks need improvement.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $107.07 vs MA200 $84.00
Failing evidence
Volume expansion above averageVolume ratio 0.98x
6/7 checks
Watch
Livermore B

Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$107.07
Relative strengthRS 87
Failing evidence
Volume vs average0.98x
Pivotal point cleared on expanding volumeNot confirmed
4/6 checks
Watch
Darvas B

Box-theory read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$107.07
Relative strengthRS 87
Failing evidence
Volume vs average0.98x
Box top broken on heavy volumeNot confirmed
4/6 checks
Watch
Wyckoff B

Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$107.07
Relative strengthRS 87
Failing evidence
Volume vs average0.98x
Sign of Strength confirmed on expanding volume0.98x average volume — needs ≥1.4x
4/6 checks
Breakout Health

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising
155RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +6 A+
A: 18 D: 12 Net: +665 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini SEPA criteria · 4/7 met
B 4/7 SEPA
Separate score from the 8-point Trend Template (8/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ +136%
Revenue growth ≥20% YoY +8%
Gross margin ≥30% 14%
ROE ≥17% 4%
RS rating ≥80 (leadership) 87
Stage 2 uptrend (Weinstein) Stage 2
Within 25% of 52W high -3.3%

Method Playbook

📋 Trade it like Wyckoff EXACT LEVELS · PRO
Minervini O'Neil Livermore Weinstein Darvas Wyckoff
Wyckoff B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro level
Published-method rule: Use the Spring/test, Sign of Strength, creek, or Last Point of Support boundary identified by the active structure.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require a completed test or Sign of Strength/Last Point of Support confirmation with improving demand versus supply.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Start below the Spring/test low or structural support whose failure would invalidate the accumulation read.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Raise protection beneath successive Last Points of Support or meaningful higher lows during markup; never loosen it.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit on a failed Sign of Strength, support loss, or clear supply-dominant reversal such as an upthrust failure.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

Wyckoff SOS ⚠ Extended past buy zone ⚠ 3rd-stage base ⚠ Not actionable yet
55.0 score
RS Score 87
Trend 8/8
CANSLIM 76.6* (B)
range low: 72.56 range high: 89.647 range pct: 0.235 sos thrust: 0.188 sos vol ratio: 1.473 sos bars ago: 7 near lps: ✗ validation reason: valid generic setup multi tf evaluated: ✓ multi tf reason: weekly: MA stabilizing or rising — accumulation context supported
Why This Setup?
Wyckoff SOS

SOS: breakout above range_high=89.65, thrust=18.8%, vol=1.5x avg, lps=extended, 7 bars ago | Strong trend (8/8) | Top RS (87) | Moderate pattern (63%) | Power Trend | Stage 2 | Readiness 63/100 (early) | CANSLIM 76.6 (B) | ⚠ Extended past buy zone; 3rd-stage base; Not actionable yet

The Universal Edge Check

The panel is uneasy

Too many universals unmet — this leans closer to a guess than a trade.

2/7 universals met
Why these seven? → The Universal Edge

Minervini Trend Template

8/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $107.07 vs SMA150 $85.67 / SMA200 $84.00
SMA 150 above SMA 200 SMA150 $85.67 vs SMA200 $84.00
SMA 200 trending up Slope +3.03 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $100.27
Price above SMA 50 $107.07 vs SMA50 $100.27
30%+ above 52W low +81.5% from $58.99
Within 25% of 52W high -3.3% from $110.68
RS score above 70 RS 87

Fundamentals

52W Range
93%
Mkt Cap SEC
136.6B
EPS QoQ
+136%
Rev YoY
+8%
ROE
4%
Gross Margin
14%
D/E
0.86
EPS TTM
$1.39
P/E TTM
77.0x
Float
1.3B
Insider
No Buy

Company

Legend AI snapshot
CVS Health Corporation
CVS · NYSE · Retail Trade · Drugstore Chains
$107.07latest close $136.6Bmarket cap 90RS rank 55setup score
O'Neil · Grade Card
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
B 76.6* CANSLIM * disqualified on M
C · Curr. EPS
100
A · Annual EPS
62
N · New Highs
100
S · Supply/Demand
70
L · Leader RS
87
I · Inst. Spons.
96
M · Market
30

Weekly Context

Multi-timeframe signals from weekly bars
W. Trend
8/8
W. RS
100
W. Support
$69.51
W. Resist
$110.68
Weekly Structure

Scan History

20× streak
Jul 24: 94 (Trend Only)Jul 24: 94 (Trend Only)Jul 27: 94 (Trend Only)Jul 28: 55 (Wyckoff SOS)55
Jul 28
Wyckoff SOS ✓ Gate
55
Jul 27
Trend Only ✓ Gate
94 0.0%
Jul 24
Trend Only ✓ Gate
94 -0.6%
Jul 24
Trend Only ✓ Gate
94 -0.6%

Get the full picture on CVS

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.

Start 7-Day Free Trial